R1 RCM has received a noncompliance notice from Nasdaq’s Listing Qualifications Department resulting from R1’s delay in filing its quarterly report on Form 10-Q for the third quarter of 2023. Nasdaq’s ...
R1 (“R1” or the “Company”), the leader in healthcare revenue management, has been named a 2026 ‘Best in KLAS’ award winner ...
MURRAY, Utah, June 17, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial ...
MURRAY, Utah, Nov. 02, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare ...
R1 RCM has received an investment from venture capital firm Khosla Ventures to further its push into AI-powered healthcare revenue cycle transformation. Khosla Ventures is a leading backer of AI ...
New Mountain Capital is offering to buy out other investors in revenue cycle management giant R1 RCM for $13.75 a share in cash. The private equity firm’s offer represents a 24% premium to R1’s ...
MURRAY, Utah, Dec. 06, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of ...
(Reuters) -R1 RCM said on Thursday private-equity firms TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R) would acquire the healthcare technology company in a deal that values it at $8.9 ...
Leerink Partners analyst Michael Cherny reiterated a Buy rating on R1 RCM (RCM – Research Report) on March 7 and set a price target of $17.00. Michael Cherny has given his Buy rating due to a ...
Fintel reports that on February 28, 2024, Barclays downgraded their outlook for R1 RCM (NasdaqGS:RCM) from Overweight to Equal-Weight. As of February 24, 2024, the average one-year price target for R1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results